Preliminary nonclinical toxicity, pharmacokinetics, and pharmacodynamics of ALXN4100TPO, a thrombopoietin receptor agonist, in CD2F1 mice

International Journal of Toxicology

Volumn 32, Issue 2, 2013, Pages 100-112

  Satyamitra, Merriline ^a   Lombardini, Eric ^a   Peng, Tao ^b   Devore, Denise ^b   Graves III, John ^a   Mullaney, Conor ^a   Ney, Patrick ^a   Srinivasan, Venkataraman ^a  

^a UNIFORMED SERVICES UNIVERSITY OF THE HEALTH SCIENCES   (United States)

^b ALEXION PHARMACEUTICALS   (United States)

Author keywords

drug development; megakaryopoiesis; nonclinical safety evaluation; platelets; single dose toxicity; thrombopoietin receptor agonist

Indexed keywords

ALXN 4100TPO; RECOMBINANT THROMBOPOIETIN; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL TISSUE; AREA UNDER THE CURVE; ARTICLE; BEHAVIOR CHANGE; BONE MARROW CELL; CELL LINEAGE; CLINICAL OBSERVATION; CONTROLLED STUDY; CONVULSION; DIARRHEA; DRUG HALF LIFE; DRUG SAFETY; EXTRAMEDULLARY HEMATOPOIESIS; FEMALE; HEMATOLOGY; HEMATOPOIETIC TISSUE; HISTOPATHOLOGY; HUMAN; HUMAN CELL; INJECTION SITE IRRITATION; LETHARGY; LIVER; LYMPHOID CELL; MALE; MAXIMUM PLASMA CONCENTRATION; MEGAKARYOPOIESIS; MOUSE; NONHUMAN; SALIVATION DISORDER; SIDE EFFECT; SPLEEN; THROMBOCYTE COUNT; TIME TO MAXIMUM PLASMA CONCENTRATION; TREMOR; WEIGHT CHANGE;

ANIMALS; ANTIBODIES, MONOCLONAL; BIOLOGICAL AVAILABILITY; BLOOD PLATELETS; BONE MARROW; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG EVALUATION, PRECLINICAL; FEMALE; MALE; MICE; MICE, INBRED STRAINS; PLATELET COUNT; RECEPTORS, THROMBOPOIETIN; SPLEEN; THROMBOCYTOPENIA; THROMBOPOIESIS; THROMBOPOIETIN;

MUS;

EID: 84875943335     PISSN: 10915818     EISSN: 1092874X     Source Type: Journal    
DOI: 10.1177/1091581813482336     Document Type: Article

References (28)

1. DiCarlo AL, Poncz M, Cassatt DR, Shah JR, Czarniecki CW, Maidment BW. Development and licensure of medical countermeasures for platelet regeneration after radiation exposure. Radiat Res. 2011 ; 176 (1). 134-137
2. Hokom MM, Lacey D, Kinstler OB, et al. Pegylated megakaryocyte growth and development factor abrogates the lethal thrombocytopenia associated with carboplatin and irradiation in mice. Blood. 1995 ; 86 (12). 4486-4492
3. Kaushansky K, Broudy VC, Grossmann A, et al. Thrombopoietin expands erythroid progenitors, increases red cell production, and enhances erythroid recovery after myelosuppressive therapy. J Clin Invest. 1995 ; 96 (3). 1683-1687
4. Kaushansky K, Lin N, Grossmann A, Humes J, Sprugel KH, Broudy VC. Thrombopoietin expands erythroid, granulocyte-macrophage, and megakaryocytic progenitor cells in normal and myelosuppressed mice. Exp Hematol. 1996 ; 24 (2). 265-269
5. Grossmann A, Lenox J, Ren HP, et al. Thrombopoietin accelerates platelet, red blood cell, and neutrophil recovery in myelosuppressed mice. Exp Hematol. 1996 ; 24 (10). 1238-1246
6. Akahori H, Shibuya K, Obuchi M, et al. Effect of recombinant human thrombopoietin in nonhuman primates with chemotherapy-induced thrombocytopenia. Br J Hematol. 1996 ; 94 (4). 722-728
7. Farese AM, Hunt P, Grab LB, MacVittie TJ. Combined administration of recombinant human megakaryocyte growth and development factor and granulocyte colony-stimulating factor enhances multilineage hematopoietic reconstitution in nonhuman primates after radiation-induced marrow aplasia. J Clin Invest. 1996 ; 97 (9). 2145-2151
8. Wagemaker G, Neelis KJ, Hartong SC, et al. The efficacy of recombinant thrombopoietin in murine and nonhuman primate models for radiation-induced myelosuppression and stem cell transplantation. Stem Cells. 1998 ; 16 (6). 375-386
9. Kuter DJ. Thrombopoietin and thrombopoietin mimetics in the treatment of thrombocytopenia. Ann Rev Med. 2009 ; 60: 193-206
10. Kuter DJ, Mufti GJ, Bain BJ, Hasserjian RP, Davis W, Rutstein M. Evaluation of bone marrow reticulin formation in chronic immune thrombocytopenia patients treated with romiplostim. Blood. 2009 ; 114 (18). 3748-3756
11. George JN, Terrell DR. Novel thrombopoietic agents: a new era for management of patients with thrombocytopenia. Haematologica. 2008 ; 93 (10). 1445-1449
12. Frederickson S, Renshaw MW, Lin B, et al. A rationally designed agonist antibody fragment that functionally mimics thrombopoietin. Proc Natl Acad Sci USA. 2006 ; 103 (39). 14307-14312
13. Satyamitra M, Lombardini E, Graves J, et al. A TPO receptor agonist, ALXN4100TPO, mitigates radiation-induced lethality and stimulates hematopoiesis in CD2F1 mice. Radiat Res.. 2011 ; 175 (6). 746-758
14. Wild MA, Xin H, Maruyama T, et al. Human antibodies from immunized donors are protective against anthrax toxin in vivo. Nat Biotechnol. 2003 ; 21 (11). 1305-1306
15. Harris N, Kunicka J, Kratz A. The ADVIA 2120 hematology system: flow cytometry-based analysis of blood and body fluids in the routine hematology laboratory. Lab Hematol. 2005 ; 11 (1). 47-61
16. Olnes MJ, Scheinberg P, Calvo KR, et al. Eltrombopag and improved hematopoiesis in refractory aplastic anemia. New Eng J Med. 2012 ; 367 (1). 11-19
17. Wang B, Nichol JL, Sullivan JT. Pharmacodynamics and pharmacokinetics of AMG 531, a novel thrombopoietin receptor ligand. Clin Pharmacol Therap. 2004 ; 76 (6). 628-638
18. Jenkins JM, Williams D, Deng Y, et al. Phase 1 clinical study of eltrombopag, an oral, nonpeptide thrombopoietin receptor agonist. Blood. 2007 ; 109 (11). 4739-4741
19. Vial T, Descotes J. Clinical toxicity of interleukin-2. Drug Saf. 1992 ; 7 (6). 417-433
20. Bree AG, Schlerman FJ, Kaviani MD, Hastings RC, Hitz SL, Goldman SJ. Multiple effects on peripheral hematology following administration of recombinant human interleukin 12 to nonhuman primates. Biochem Biophys Res Commun. 1994 ; 204 (3). 1150-1157
21. Atkins MB, Kappler K, Mier JW, Isaacs RE, Berkman EM. Interleukin-6-associated anemia: determination of the underlying mechanism. Blood. 1995 ; 86 (4). 1288-1291
22. Gollob JA, Veenstra KG, Mier JW, Atkins MB. Agranulocytosis and hemolytic anemia in patients with renal cell cancer treated with interleukin-12. J Immunother. 2001 ; 24 (1). 91-98
23. Satyamitra MM, Graves J, Mullaney CP, Srinivasan V. Proceedings of the 14th International Congress of Radiation Research; Poster No. POS23-63, Warszawa, Poland. 2011 :
24. Kuter DJ. Biology and chemistry of thrombopoietic agents. Sem Hematol. 2010 ; 47 (3). 243-248
25. Johns JL, Christopher MM. Extramedullary hematopoiesis: a new look at the underlying stem cell niche, theories of development, and occurrence in animals. Vet Pathol. 2012 ; 49 (3). 508-523
26. Douglas VK, Tallman MS, Cripe LD, Peterson LC. Thrombopoietin administered during induction chemotherapy to patients with acute myeloid leukemia induces transient morphologic changes that may resemble chronic myeloproliferative disorders. Am J Clin Pathol. 2002 ; 117 (6). 844-850
27. Li J, Yang C, Xia Y, et al. Thrombocytopenia caused by the development of antibodies to thrombopoietin. Blood. 2001 ; 98 (12). 3241-3248
28. Pharmacology/toxicology review and evaluation of Nplate (romiplostim). FDA Pharmacology Reviews. 2008 ;: